CENTENE CORP Q3 FY2026 earnings call

• Financial Outperformance: Adjusted diluted EPS was $0.58, beating prior expectations and driving an upward revision in full-year guidance.
• Medicaid Stability: Core cost trends stabilized, particularly in behavioral health and home health. States are proactively incorporating work requirement acuity impacts into 2027 rate drafts, reducing uncertainty.
• Medicare Turnaround: Medicare Advantage is achieving break-even one year early due to favorable medical cost experience and discipline management. PDP performance improved due to prudent bidding and cost structure optimization.
• Marketplace Recovery: The Marketplace business demonstrated strong underlying fundamentals, absorbing impacts from CMS unauthorized enrollment crackdowns and Independent Dispute Resolution (IDR) issues without missing targets.
• Operational Efficiency: SG&A expense ratio improved to 6.5% in Q3 (vs 7.0% prior year) due to workforce optimization and automation initiatives.
• Innovation & Care: Highlighted success in using data-driven supplemental benefits (e.g., healthy food programs) to lower claims spend by ~$200 per member per month and improve clinical outcomes.

The transcript does not provide specific absolute revenue figures or percentage contribution breakdowns for individual product segments (Medicaid, Medicare, Marketplace). However, it details the financial performance trends: Medicaid maintained a Health Benefit Ratio (HBR) of 93.6%, tracking toward a full-year target of 93.5%. The Medicare segment exceeded expectations, with Medicare Advantage on track to achieve break-even results in 2026 (a year ahead of schedule) and Standalone Part D (PDP) forecasting pre-tax margins in the mid-to-high threes. The Marketplace business significantly outperformed, moving its full-year pre-tax margin expectation up to the top of the previous range (4.5% to 5%).

• Full-Year 2026 Adjusted Diluted EPS: Raised to greater than $5.20 (previously >$4.80).
• Consolidated HBR: Improved by 15 basis points at the midpoint, driven by better-than-expected Medicare and Commercial performance.
• Medicaid HBR: Maintained full-year forecast of approximately 93.5%.
• Medicare Advantage: On track to reach break-even financial results in 2026.
• Part D (PDP): Forecasted pre-tax margins in the mid-to-high threes (up from >3% previously).
• Marketplace: Full-year pre-tax margin expected at the top of the previous range of 4.5% to 5%.
• SG&A Expense Ratio: Full-year midpoint held at 7.2%.
• Investment Income: Maintained guidance of approximately $1.5 billion.

• Medicaid Acuity/Rate Dislocation: Potential mismatch between Medicaid rates and acuity levels due to OB-3 eligibility terminations and work requirements.
• Membership Attrition: Expected 8-9% year-over-year decline in Medicaid membership by year-end 2026 due to redeterminations and policy changes.
• Policy Uncertainty: Implementation timelines for work requirements vary by state; potential disruptions from midterm election leadership changes.
• Program Integrity Risks: Ongoing challenges with CMS crackdowns on unauthorized enrollments and broker fraud in the Marketplace.
• IDR and No Surprises Act: Continued headwinds from providers gaming the Independent Dispute Resolution process.

Q: Analyst asked about Medicaid rate dialogue with states, specifically how they account for work requirement acuity shifts in the 1-1 cohort. / A: CEO stated that states are actively engaging and explicitly including provisions for work requirement acuity shifts in draft rates, leveraging better data from the redetermination period. This proactive approach de-risks the gap between rates and acuity compared to past cycles.

Q: Analyst asked if the PDP margin 'reset' for 2027 would return to the initial 2% target or the current 3% benchmark. / A: CFO explained that while initial 2025/26 targets were suppressed by IRA subsidies, the reset for 2027 is likely in the 2-3% range initially. However, the company aims to outperform this baseline throughout the year as the subsidy effects wear off.

Q: Analyst asked about the impact of IDR catch-up costs on Q4 and why the company still expects high Marketplace margins despite these headwinds. / A: CFO clarified that the underlying strength of the Marketplace business allowed them to absorb IDR reserves and program integrity costs without impacting the bottom line. He noted that this bolus is not expected to recur in Q4, allowing the 5% pre-tax margin target to hold.

Q: Analyst asked about the magnitude of margin expansion expected in Medicare Advantage for 2027 given the early break-even achievement in 2026. / A: CEO indicated that reaching break-even a year early creates a positive jump-off point for 2027. She expects expanded margins in 2027 and beyond, supported by a refined footprint focusing on high-value populations and geographies.

Q: Analyst asked about risks regarding state leadership changes post-midterms affecting Medicaid work requirement implementation. / A: CEO expressed confidence that federal frameworks and long-standing relationships with Medicaid agencies will ensure continuity. She noted that states are taking a methodical, data-driven approach to eligibility verification, which mitigates disruption even if political leadership changes.